



WHO Pharmacovigilance & Indian Pharmacopoeia 2026

Published On: 03-01-2026

News: In January 2026, India rose to **8th position** globally in contributions to the WHO Pharmacovigilance database (VigiBase), marking a significant improvement from its 123rd rank a decade ago. This coincided with the release of the **10th Edition of the Indian Pharmacopoeia (IP 2026)**.

Key Pillars for UPSC:

- **VigiBase & Uppsala Monitoring Centre (UMC):** VigiBase is the WHO global database for Individual Case Safety Reports (ICSRs). India's jump signifies a robust reporting culture for Adverse Drug Reactions (ADRs).
- **Pharmacovigilance Programme of India (PvPI):** Launched in 2010 and coordinated by the **Indian Pharmacopoeia Commission (IPC)**, Ghaziabad. It acts as the National Coordination Centre (NCC) for monitoring drug safety.
- **Indian Pharmacopoeia (IP) 2026 Highlights:**
- **Monographs:** Includes **3,340 monographs** (121 new ones), covering anti-TB, anti-diabetic, and anti-cancer drugs.
- **Global South Leadership:** IP is now recognized in **19 countries**, facilitating "Pharma Diplomacy" and easing exports to developing nations.
- **First-time Inclusions:** 20 blood component monographs (transfusion medicine), making India a global pioneer in this standardisation.
- **Mains Value-Add:** Use this to discuss "**India as the Pharmacy of the World.**" It shifts the narrative from India being just a "volume producer" of generics to a "quality and safety leader."